GRFS
Grifols, S.A.
GRFS has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over GRFS overall, supported by stronger fundamentals and stronger modeled upside.
GRFS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Stable | |
| Weak |
GRFS's profitability is currently strong, and its revenue and cash flow are stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GRFS PE Valuation
GRFS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GRFS Forward outlook
There aren't enough analyst estimates for GRFS to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GRFS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.74 | +54% |
| Q1 2026 | $0.68 | +113% |
| Q4 2025 | $0.65 | +160% |
| Q3 2025 | $0.61 | +165% |
| Q2 2025 | $0.48 | +100% |
| Q1 2025 | $0.32 | +10% |
| Q4 2024 | $0.25 | +8.7% |
| Q3 2024 | $0.23 | +28% |
GRFS has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GRFS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.1B | -0.9% |
| Q1 2026 | $1.9B | -3.2% |
| Q4 2025 | $2.2B | -0.6% |
| Q3 2025 | $2.1B | +4% |
| Q2 2025 | $2.1B | +4% |
| Q1 2025 | $2B | +9.8% |
| Q4 2024 | $2.2B | +12% |
| Q3 2024 | $2B | +12% |
GRFS's revenue grew through 2024 and has held roughly level since: $2.1B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 18% | -0.9 points |
| Q1 2026 | 15% | -0.4 points |
| Q4 2025 | 14% | -5 points |
| Q3 2025 | 21% | +2.9 points |
| Q2 2025 | 18% | +2 points |
| Q1 2025 | 15% | +2.5 points |
| Q4 2024 | 19% | +4.4 points |
| Q3 2024 | 18% | +2 points |
GRFS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GRFS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GRFS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $120M | +14% |
| Q1 2026 | $65.5M | -32% |
| Q4 2025 | $329.6M | -28% |
| Q3 2025 | $283.7M | +19% |
| Q2 2025 | $105.6M | -57% |
| Q1 2025 | $95.9M | +$321.4M |
| Q4 2024 | $460.5M | +444% |
| Q3 2024 | $239.2M | +203% |
GRFS generated $799M in free cash flow over the past year, down 11% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GRFS on cash flow, with more consistent year-over-year improvement.
GRFS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.2% | -8M shares |
| 3 years | +0.3% | +2M shares |
| 5 years | +6.8% | +43.2M shares |
| Available history | -0.5% | -3.6M shares |
GRFS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
GRFS hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GRFS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 4.6x | High |
| Q1 2026 | 5.4x | High |
| Q4 2025 | 4.7x | High |
| Q3 2025 | 5.6x | High |
| Q2 2025 | 5.0x | High |
| Q1 2025 | 6.2x | High |
| Q4 2024 | 6.3x | High |
| Q3 2024 | 6.5x | High |
GRFS's net debt is about 4.6 years of its operating earnings (EBITDA), down from 5.0 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over GRFS on leverage, with a lower net debt burden relative to earnings.
GRFS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.4 | Neutral |
| Stochastic | 84.5 | Overbought |
GRFS's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GRFS PE vs Healthcare Sector
| Metric | GRFS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GRFS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GRFS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.83 | 12% above |
| 20 week MA | $7.69 | 14% above |
| 50 week MA | $8.15 | 8% above |
| 100 week MA | $8.36 | 5.3% above |
| 200 week MA | $8.39 | 4.9% above |
GRFS has climbed back above all five of its weekly moving averages, and it's now 4.9% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
GRFS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.5 | $18.7 | -21% |
| 2021 | $18.7 | $11.2 | -40% |
| 2022 | $11.2 | $8.12 | -27% |
| 2023 | $8.12 | $11.6 | +42% |
| 2024 | $11.6 | $7.65 | -34% |
| 2025 | $7.65 | $9.10 | +19% |
| 2026 YTD | $9.10 | $8.80 | -3.3% |
GRFS has finished lower in four of the last six years. It's down 3.3% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GRFS on returns for 2026, with the stronger performance.